1. Economy Sub-Committee Meeting 22nd April 2013 Jonathan Wilson, Programme Manager Scottish Enterprise Economy Sub-Committee Meeting 22nd April 2013 Jonathan Wilson, Programme Manager Scottish Enterprise

2. Life Science Global View Reduction in size of Large Pharma but industry Growth …but healthcare related employment predicted to be largest growth sector in US …therefore this increase in employment must come from elsewhere: EU data indicates a 4% increase in employees in biotech (2010-2011) to a total of 48,330 US data indicates a 5% increase in biotech (2010-2011) to a total of 98,560 (E&Y) Continued economic downturn and increasing uncertainty Move towards outsourcing and partnering  convergence, with further integration between drugs and devices  use of IT to accelerate discovery and drive down costs  emphasis on search for alternative uses for existing approved drugs  collaboration opportunities as larger companies look to bolster pipelines.

3. Brain and Body Institute 2016 No.9 2012 SCRM 2012 NHS provision Hotel Operator MOB2, Retail, Car Park Sick Kids 2015 Anne Rowling Institute 2013 Delivering the Vision 5 MRC Centres; British Heart Foundation Centre (1 of 4 in UK) ; and the Wellcome Millennium Clinical Research Facility (1 of 6 in the UK).

4. Life Sciences UK View LS sector still key for economic growth in US, Europe, UK and Scotland - Employment is growing in Scotland in the LS sector (18.1% 2010-2011) Bio-campuses are developing in the UK (Cambridge and Nottingham) and Europe (Eindhoven) - it is important that we consolidate the lead we have established. R&D intensive teams and businesses are wanting to work collaboratively, particularly with innovative academics and SMEs. Inward investment drawn to ‘honey pot’ of excellent academic research, world class clinical facilities and a diverse cluster of innovative growing companies. Market research indicates growing companies are looking for flexible, high quality, turnkey accommodation. (Access to finance, good transport links and quality ancillary development is considered important.)

5. BioQuarter Objectives A top 10 global cluster for biomedical research Private investment of £250m, accommodation onsite for 6,000 by year 25 (6,800 net jobs at the Scottish level) Attract (and retain) world-class companies and talent to Scotland Stimulate interaction between commercial, clinical & academic experts Boost the formation and growth of new ventures Create overall net GVA impact of £1 billion

6. BioQuarter delivery 2012/13 Scottish Enterprise Tenant attraction –10 at Nine Ground floor 63% occupied (8% under offer) First floor 5% occupied (8.5% under offer) Second floor 0% occupied IRO 60 jobs New Masterplan New marketing resourcing and collateral updates Stage 5 Review: amber Investment Committee Review: plans endorsed

7. BioQuarter delivery 2012/13 NHS Lothian Anne Rowling Clinic open Sick Kids procurement underway Impact of new CEO strategic thinking –Expansion of current facilities –Outpatients

8. BioQuarter delivery 2012/13 University of Edinburgh –CIP, SCRM 2 –Commercialisation programme since inception: Over 300 new technology opportunities disclosed and assessed 150 entries into BioQuarter’s Innovation Competition Over £33m of commercialisation funding raised for translational research 7 new life science companies created 12 further company prospects currently in ‘incubation’ – 8 of these ‘High Growth’ 77 collaborative industrial contracts signed with a value of nearly £12m £36m of new life science venture capital attracted to Edinburgh

9. Looking Forward Develop a roadmap for further infrastructure development. Maximise private/public partner relationships. Improve facilitation of strategic collaborations between tenants and the wider campus. Continue support for the Commercialisation programme. Increase specialist Business Development and Marketing activity.

10. © Allan Murray Architects 2013 Looking Forward: Masterplan

12. Summary of Key Changes Increased density – upto 295,000 sqm (subject to multi-storey parking) Increased heights on Phase 4 Predominantly lifescience (245,000 sqm) with supporting mixed uses Buildings fronting onto streets with active frontages along key routes Fixed transport routes with flexible urban blocks Strong linkages through site and into adjacent communities  Urban dominant, not landscape dominant model – “a piece of city”

13. BioQuarter is a life science commercialisation partnership between five key organisations Delivery Partners